# Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

> **NCT07101588** · PHASE4 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

## Interventions

- **COMBINATION_PRODUCT:** Ruxolitinib, Decitabine

## Key facts

- **NCT ID:** NCT07101588
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-12-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101588, "Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07101588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*